- Home
- AMIX vs INM Comparison
AMIX vs INM Comparison
Compare AMIX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- INM
- Stock Information
- Founded
- AMIX 2014
- INM 1981
- Country
- AMIX United States
- INM Canada
- Employees
- AMIX N/A
- INM N/A
- Industry
- AMIX
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- INM Health Care
- Exchange
- AMIX NYSE
- INM Nasdaq
- Market Cap
- AMIX 3.5M
- INM 3.2M
- IPO Year
- AMIX N/A
- INM N/A
- Fundamental
- Price
- AMIX $1.25
- INM $3.33
- Analyst Decision
- AMIX Strong Buy
- INM
- Analyst Count
- AMIX 1
- INM 0
- Target Price
- AMIX $5.00
- INM N/A
- AVG Volume (30 Days)
- AMIX 2.5M
- INM 9.5M
- Earning Date
- AMIX 08-12-2025
- INM 05-12-2025
- Dividend Yield
- AMIX N/A
- INM N/A
- EPS Growth
- AMIX N/A
- INM N/A
- EPS
- AMIX N/A
- INM N/A
- Revenue
- AMIX N/A
- INM $4,920,990.00
- Revenue This Year
- AMIX N/A
- INM N/A
- Revenue Next Year
- AMIX N/A
- INM N/A
- P/E Ratio
- AMIX N/A
- INM N/A
- Revenue Growth
- AMIX N/A
- INM N/A
- 52 Week Low
- AMIX $1.14
- INM $1.72
- 52 Week High
- AMIX $42.40
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- AMIX 35.38
- INM 59.24
- Support Level
- AMIX $1.14
- INM $2.26
- Resistance Level
- AMIX $1.36
- INM $5.50
- Average True Range (ATR)
- AMIX 0.10
- INM 0.40
- MACD
- AMIX 0.00
- INM 0.11
- Stochastic Oscillator
- AMIX 26.83
- INM 37.04
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.